Skip to main content
SpringerLink
Log in

Pharmacogenomics of Osteoporosis-Related Bone Fractures

  • Chapter
  • First Online:
Omics for Personalized Medicine

Abstract

Osteoporosis is a systemic skeletal disease characterised by low bone mass and deterioration in the microstructure of bone tissue, which causes bone fragility and consequent increase in fracture risk. The lifetime fracture risk of a patient with osteoporosis is as high as 40 %, and fractures most commonly occur in the hip, spine or wrist. From a patient’s perspective, a fracture and the subsequent loss of mobility and autonomy often represent a major drop in the quality of life. Additionally, osteoporotic fractures of the hip and spine carry a 12-month excess mortality of up to 20 %, because they require hospitalisation and they subsequently present enhanced risk of other complications, such as pneumonia or thromboembolic disease due to chronic immobilisation.

On the other hand, osteoporosis is a multifactorial and polygenic disease, so the individual likelihood of having a fracture depends on the combination of several risk factors such as low bone mineral density (BMD) and genetic predisposition.

This chapter will present the most interesting concerns related to pharmacogenetics of the pathologies most prevalent in the elderly population. It will identify fracture risk and estimation of the probability of major osteoporotic fracture by assessment tools. The genetics of osteoporosis will be approached by showing general pathways involved in bone homeostasis and polymorphisms of genes related with BMD and osteoporotic fractures. Genetic or genomic screening approaches that have been used and also potential benefits from other existing or emerging technologies/approaches will be discussed. In addition, the pharmacogenetics of osteoporosis will be discussed, in particular antiresorptive medications, reviewing efficacy limitations and adverse drug reactions associated with current osteoporosis treatments and how these could be attributed to genetic factors. Additionally, it will analyse the therapeutic targets in osteoporosis (bone anabolic and bone resorptive) and the development of new antiresorptive therapies. Furthermore, gene–environment, age and gender differences interactions known to affect response to osteoporosis treatment will be considered. Finally, the translation of pharmacogenetic findings to the clinical practice will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467:1061–1073

    Article  CAS  Google Scholar 

  • Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239–244

    Article  CAS  PubMed  Google Scholar 

  • Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE (2005) Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 90:4566–4572

    Article  CAS  PubMed  Google Scholar 

  • Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE (2009) Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int 20:1259–1266

    Article  CAS  PubMed  Google Scholar 

  • Arko B, Prezelj J, Komel R, Kocijancic A, Marc J (2002) No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol 81:147–152

    Article  CAS  PubMed  Google Scholar 

  • Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M, Güell S, Puchol N, Gene E, Casado E, Sancho P, Solà S, Torán P, Iglesias M, Sabaté V, López-Expósito F, Ortiz S, Fernandez Y, Diez-Perez A (2011) Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord 12:30

    Article  PubMed Central  PubMed  Google Scholar 

  • Balan G, Bauman J, Bhattacharya S, Castrodad M, Healy DR, Herr M, Humphries P, Jennings S, Kalgutkar AS, Kapinos B, Khot V, Lazarra K, Li M, Li Y, Neagu C, Oliver R, Piotrowski DW, Price D, Qi H, Simmons HA, Southers J, Wei L, Zhang Y, Paralkar VM (2009) The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 19:3328–3332

    Article  CAS  PubMed  Google Scholar 

  • Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348–360

    Article  CAS  PubMed  Google Scholar 

  • Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effect of Denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157

    Article  CAS  PubMed  Google Scholar 

  • Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947

    PubMed  Google Scholar 

  • Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR (1992) Requirement of pp 60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:1622–1627

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34

    PubMed Central  PubMed  Google Scholar 

  • Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trail. J Bone Miner Res 24:153–161

    Article  CAS  PubMed  Google Scholar 

  • Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475

    Article  PubMed  Google Scholar 

  • Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916

    Article  CAS  PubMed  Google Scholar 

  • Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882

    Article  CAS  PubMed  Google Scholar 

  • Cheung CL, Xiao SM, Kung AW (2010) Genetic epidemiology of age-related osteoporosis and its clinical applications. Nat Rev Rheumatol 6:507–517

    Article  PubMed  Google Scholar 

  • Cho C, Nuttall M (2002) Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. Expert Opin Ther Targets 6:679–689

    Article  CAS  PubMed  Google Scholar 

  • Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, Yoon D, Lee MH, Kim DJ, Park M, Cha SH, Kim JW, Han BG, Min H, Ahn Y, Park MS, Han HR, Jang HY, Cho EY, Lee JE, Cho NH, Shin C, Park T, Park JW, Lee JK, Cardon L, Clarke G, McCarthy MI, Lee JY, Lee JK, Oh B, Kim HL (2009) A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 41:527–534

    Article  CAS  PubMed  Google Scholar 

  • Choi HJ, Choi JY, Cho SW, Kang D, Han KO, Kim SA, Kim SY, Chung YS, Shin CS (2010) Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J 51:231–238

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, Bates D, Black DM (2002) Clinical use of bone densitometry: scientific review. JAMA 288:1889–1897

    Article  PubMed  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial FREEDOM (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  • Cummings-Vaughn LA, Gammack JK (2010) Falls, osteoporosis and hip fractures. Med Clin North Am 95:495–506

    Article  Google Scholar 

  • Dagdelen S, Sener D, Bayraktar M (2007) Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 24:1314–1320

    Article  CAS  PubMed  Google Scholar 

  • Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta analyses. J Bone Miner Res 19:330–337

    Article  CAS  PubMed  Google Scholar 

  • Delmas PD, Rizzoli R, Cooper C, Reginster JY (2005) Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16:1–5

    Article  PubMed  Google Scholar 

  • Eisman JA (1999) Genetics of osteoporosis. Endocr Rev 20(6):788–804

    Article  CAS  PubMed  Google Scholar 

  • Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–14367

    Article  CAS  PubMed  Google Scholar 

  • European Agency for the Evaluation of Medicinal Products-Committee for Proprietary Medicinal Products (2002) Position paper on terminology in pharmacogenetics EMEA/CPMP/3070/01. Available at: http://www.eurogentest.org/uploads/1165308837041_Pharmacogenetics.pdf

  • European Medicines Agency (2009) Pre authorisation evaluation of medicines for human use: denosumab. Available at: www.ema.europa.eu/pdfs/human/opinion/Prolia_77616809en.pdf

  • Fang Y, Rivadeneira F, van Meurs JB, Pols HA, Ioannidis JP, Uitterlinden AG (2006) Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone 39:938–945

    Article  CAS  PubMed  Google Scholar 

  • Franken AA, van Blijderveen NJ, Witjes MJ, Netelenbos CJ (2011) Bisphosphonate-related osteonecrosis of the jaw. Ned Tijdschr Geneeskd 155:A3077

    PubMed  Google Scholar 

  • Garnero P, Munoz F, Borel O, Sornay-Rendu E, Delmas PD (2005) Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density. J Clin Endocrinol Metab 90:4829–4835

    Article  CAS  PubMed  Google Scholar 

  • Gates BJ, Sonnett TE, Duvall CA, Dobbins EK (2009) Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 7:293–323

    Article  CAS  PubMed  Google Scholar 

  • Gauthier JY, Chauret N, Cromlish W, Desmarais S, le Duong T, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928

    Article  CAS  PubMed  Google Scholar 

  • Gervasini G, Benítez J, Carrillo JA (2010) Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 66:755–774

    Article  CAS  PubMed  Google Scholar 

  • Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595–1604

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413

    Article  CAS  PubMed  Google Scholar 

  • Gurwitz D (2010) Pharmacogenetics education: 10 years of experience at Tel Aviv University. Pharmacogenomics 11:647–649

    Article  PubMed  Google Scholar 

  • Guzel O, Guner E (2009) ISO 15189 Accreditation: requirements for quality and competence of medical laboratories, experience of a laboratory. Clin Biochem 42:274–278

    Article  PubMed  Google Scholar 

  • Haney EM, Bliziotes M (2008) Male osteoporosis: new insights in an understudied disease. Curr Opin Rheumatol 20:423–428

    Article  PubMed  Google Scholar 

  • Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, Eastell R (2010) Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25:463–471

    Article  CAS  PubMed  Google Scholar 

  • Harada S, Rodan G (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349–355

    Article  CAS  PubMed  Google Scholar 

  • Harding B, Curley AJ, Hannan FM, Christie PT, Bowl MR, Turner JJ, Barber M, Gillham-Nasenya I, Hampson G, Spector TD, Thakker RV (2006) Functional characterization of calcium sensing receptor polymorphisms and absence of association with indices of calcium homeostasis and bone mineral density. Clin Endocrinol (Oxf) 65(5):598–605

    Article  CAS  Google Scholar 

  • Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O, European Vertebral Osteoporosis Study (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61–68

    Article  CAS  PubMed  Google Scholar 

  • Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR (2005) Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail 27:155–161

    CAS  PubMed  Google Scholar 

  • Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Osteoporosis Task Force AACE (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564

    Article  PubMed  Google Scholar 

  • Hoeppner L, Secreto F, Westendorf J (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hsu YH, Zillikens MC, Wilson SG, Farber CR, Demissie S, Soranzo N, Bianchi EN, Grundberg E, Liang L, Richards JB, Estrada K, Zhou Y, van Nas A, Moffatt MF, Zhai G, Hofman A, van Meurs JB, Pols HA, Price RI, Nilsson O, Pastinen T, Cupples LA, Lusis AJ, Schadt EE, Ferrari S, Uitterlinden AG, Rivadeneira F, Spector TD, Karasik D, Kiel DP (2010) An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. PLoS Genet 6(6):e1000977

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Huang QY, Recker RR, Deng HW (2003) Searching for osteoporosis genes in the post-genome era: progress and challenges. Osteoporos Int 14:701–715

    Article  PubMed  Google Scholar 

  • Ichikawa S, Koller DL, Johnson ML, Lai D, Xuei X, Edenberg HJ, Klein RF, Orwoll ES, Hui SL, Foroud TM, Peacock M, Econs MJ (2006) Human ALOX12, but not ALOX15, is associated with BMD in white men and women. J Bone Miner Res 21:556–564

    Article  CAS  PubMed  Google Scholar 

  • Ioannidis JP (2005) Why most published research findings are false? PLoS Med 2:696–701

    Google Scholar 

  • Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, Gennari L, Albagha O, Ralston SH, Tsatsoulis A, ER-alpha Genetics Meta-Analysis (2002) Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 17:2048–2060

    Article  CAS  PubMed  Google Scholar 

  • Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG, GENOMOS Study (2004) Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 292:2105–2114

    Article  CAS  PubMed  Google Scholar 

  • Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, Econs MJ, Karasik D, Devoto M, Kammerer CM, Spector T, Andrew T, Cupples LA, Duncan EL, Foroud T, Kiel DP, Koller D, Langdahl B, Mitchell BD, Peacock M, Recker R, Shen H, Sol-Church K, Spotila LD, Uitterlinden AG, Wilson SG, Kung AW, Ralston SH (2007) Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass. J Bone Miner Res 22:173–183

    Article  CAS  PubMed  Google Scholar 

  • Ji GR, Yao M, Sun CY, Li ZH, Han Z (2010) BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: a meta-analysis. Bone 47:681–686

    Article  CAS  PubMed  Google Scholar 

  • Johnell O, Kanis JA (2006) A estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  • Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936

    Article  PubMed  Google Scholar 

  • Kapur K, Johnson T, Beckmann ND, Sehmi J, Tanaka T, Kutalik Z, Styrkarsdottir U, Zhang W, Marek D, Gudbjartsson DF, Milaneschi Y, Holm H, Diiorio A, Waterworth D, Li Y, Singleton AB, Bjornsdottir US, Sigurdsson G, Hernandez DG, Desilva R, Elliott P, Eyjolfsson GI, Guralnik JM, Scott J, Thorsteinsdottir U, Bandinelli S, Chambers J, Stefansson K, Waeber G, Ferrucci L, Kooner JS, Mooser V, Vollenweider P, Beckmann JS, Bochud M, Bergmann S (2010) Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene. PLoS Genet 6(7):e1001035. doi:10.1371/journal.pgen.1001035

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS (2011) Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 40:605–611

    Article  CAS  PubMed  Google Scholar 

  • Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81

    Article  CAS  PubMed  Google Scholar 

  • Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632–637

    CAS  PubMed Central  PubMed  Google Scholar 

  • Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS, Shea M, Waters RV, Belknap JK, Peltz G, Orwoll ES (2004) Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303:229–232

    Article  CAS  PubMed  Google Scholar 

  • Kroetz DL, Ahituv N, Burchard EG, Guo S, Sali A, Giacomini KM (2009) Institutional profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics 10:1569–1576

    Article  PubMed Central  PubMed  Google Scholar 

  • Kruk M, Ralston SH, Albagha OM (2009) LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 84:171–179

    Article  CAS  PubMed  Google Scholar 

  • Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA (2010) An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46:534–542

    Article  CAS  PubMed  Google Scholar 

  • Kurabayashi T, Matsushita H, Tomita M, Kato N, Kikuchi M, Nagata H, Honda A, Yahata T, Tanaka K (2004) Association of vitamin D and estrogen receptor gene polymorphism with the effects of long term hormone replacement therapy on bone mineral density. J Bone Miner Metab 22:241–247

    Article  CAS  PubMed  Google Scholar 

  • Lacalamita R, Schirone M, Paradiso A (2008) ISO 9001:2000 applied to a research oncology laboratory: which problems? The experience of National Cancer Institute-Bari. Ann Oncol 19:1207–1208

    Article  CAS  PubMed  Google Scholar 

  • Lamberts S, Uitterlinden A (2009) Genetic testing in clinical practice. Annu Rev Med 60:431–442

    Article  CAS  PubMed  Google Scholar 

  • Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2009) Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67:159–161

    Article  PubMed  Google Scholar 

  • Levy ME, Parker RA, Ferrell RE, Zmuda JM, Greenspan SL (2007) Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 7(3):247–252. Epub 26 Mar 2007

    Google Scholar 

  • Lewiecki EM (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 7:631–638

    Article  CAS  PubMed  Google Scholar 

  • Liu JM, Zhang MJ, Zhao L, Cui B, Li ZB, Zhao HY, Sun LH, Tao B, Li M, Ning G (2010) Analysis of recently identified osteoporosis susceptibility genes in Han Chinese women. J Clin Endocrinol Metab 95:E112–E120

    Article  PubMed  Google Scholar 

  • Lorenzo TR, Sánchez PM, Santana CL, Cobian MJL, García del Rosario C (2010) [Management of quality in an Intensive Care Unit: implementation of ISO 9001:2008 international standard]. Gestión de la calidad en una unidad de cuidados intensivos: implementación de la norma ISO9001:2008. Med Intensiva 34:476–482

    Article  Google Scholar 

  • Macdonald HM, McGuigan FE, Stewart A, Black AJ, Fraser WD, Ralston S, Reid DM (2006) Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J Bone Miner Res 21:151–162

    Article  CAS  PubMed  Google Scholar 

  • MacLaughlin E (2010) Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health system pharmacist in closing the gap. Am J Health Syst Pharm 67:4–8

    Article  Google Scholar 

  • Maize DF, Fuller SH, Hritcko PM, Matsumoto RR, Soltis DA, Taheri RR, Duncan W (2010) A review of remediation programs in pharmacy and other health professions. Am J Pharm Educ 74:25

    Article  PubMed Central  PubMed  Google Scholar 

  • Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278–1282

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mann V, Ralston SH (2003) Meta analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone 32:711–717

    Article  CAS  PubMed  Google Scholar 

  • Marc J, Prezelj J, Komel R, Kocijancic A (1999) VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 10:303–306

    Article  CAS  PubMed  Google Scholar 

  • Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A, Christiansen C, Brandi ML (2008) Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 24:2609–2615

    Article  CAS  PubMed  Google Scholar 

  • Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML (2011) Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed) 3:364–370

    Article  Google Scholar 

  • Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311–320

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

    Article  CAS  PubMed  Google Scholar 

  • Mencej-Bedrac S, Prezelj J, Kocjan T, Komadina R, Marc J (2009a) Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population. Calcif Tissue Int 85:501–506

    Article  CAS  PubMed  Google Scholar 

  • Mencej-Bedrac S, Prezelj J, Kocjan T, Teskac K, Ostanek B, Smelcer M, Marc J (2009b) The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumor necrosis factor superfamily member 11 genes are associated with bone mineral density. J Mol Endocrinol 42:239–247

    Article  CAS  PubMed  Google Scholar 

  • Murphy JE, Green JS, Adams LA, Squire RB, Kuo GM, McKay A (2010) Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am J Pharm Educ 74:7

    Article  PubMed Central  PubMed  Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2010a) Technology appraisal guidance 160 (amended January 2010): Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf

  • National Institute for Health and Clinical Excellence (NICE) (2010b) Technology appraisal guidance 161 (amended January 2010): Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/nicemedia/live/11748/47177/47177.pdf

  • Nguyen ND, Eisman JA, Center JR, Nguyen TV (2007) Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 92:955–962

    Article  CAS  PubMed  Google Scholar 

  • NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

    Article  Google Scholar 

  • Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V (2003) Raloxifene administration in postmenopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod 18:192–198

    Article  CAS  PubMed  Google Scholar 

  • Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F (2005) BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 16:943–952

    Article  CAS  PubMed  Google Scholar 

  • Patsch JM, Deutschmann J, Pietschmann P (2011) Gender aspects of osteoporosis and bone strength. Wien Med Wochenschr 161:117–123

    Article  PubMed  Google Scholar 

  • Peacock M, Koller DL, Lai D, Hui S, Foroud T, Econs MJ (2005) Sex-specific quantitative trait loci contribute to normal variation in bone structure at the proximal femur in men. Bone 37:467–473

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pharmacogenomic knowledge base (Pharmgkb) Gene, variants, pathway. Available at: http://www.pharmgkb.org/. Jan 2012

  • Pierre JM (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46:571–576

    Article  CAS  Google Scholar 

  • Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K (2009) Osteoporosis: an age-related and gender-specific disease – a mini-review. Gerontology 55:3–12

    Article  PubMed  Google Scholar 

  • Qureshi AM, Herd RJ, Blake GM, Fogelman I, Ralston SH (2002) COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int 70:158–163

    Article  CAS  PubMed  Google Scholar 

  • Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ralston SH (2002) Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 87:2460–2466

    Article  CAS  PubMed  Google Scholar 

  • Ralston SH (2010) Genetics of osteoporosis. Ann N Y Acad Sci 1192:181–189

    Article  CAS  PubMed  Google Scholar 

  • Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Scollen S, Bustamante M, Husted LB, Carey AH, Diez-Perez A, Dunning AM, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, del Monte F, Pols HA, Reeve J, Reid DM, Renner W, Rivadeneira F, van Schoor NM, Sherlock RE, Ioannidis JP, Investigators GENOMOS (2006) Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med 3:e90

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Rawadi G, Roman-Roman S (2005) Wnt signalling pathway: a new target for the treatment of Osteoporosis. Expert Opin Ther Targets 9:1063–1077

    Article  CAS  PubMed  Google Scholar 

  • Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44:4–10

    Article  CAS  PubMed  Google Scholar 

  • Reppe S, Refvem H, Gautvik VT, Olstad OK, Høvring PI, Reinholt FP, Holden M, Frigessi A, Jemtland R, Gautvik KM (2010) Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone 46:604–612

    Article  CAS  PubMed  Google Scholar 

  • Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB, Hofman A, Pols HA, Hart D, Zhai G, Kato BS, Mullin BH, Zhang F, Deloukas P, Uitterlinden AG, Spector TD (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371:1505–1512

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP, Spector TD, Genetic Factors for Osteoporosis Consortium (2009) Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 151:528–537

    Article  PubMed Central  PubMed  Google Scholar 

  • Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG, Genetic Factors for Osteoporosis (GEFOS) Consortium (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41:1199–1206

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rojo Venegas K, Aguilera Gómez M, Eisman JA, García Sánchez A, Faus Dader MJ, Calleja Hernández MA (2010) Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools. Pharmacogenomics 11:1287–1303

    Article  PubMed  Google Scholar 

  • Rojo K, Aznarte P, Calleja MA, Contreras O, Martínez JL, López-Mezquita B, Faus-Dader MJ (2010) Factors of risk in an elderly population: evaluation for the prevention of hip fractures. Rev Cir Ortop Traumatol 54:167–173

    Google Scholar 

  • Sarasquete ME, García-Sanz R, Marín L, Alcoceba M, Chillón MC, Balanzategui A, Santamaria C, Rosiñol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, González M, San Miguel JF (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–2712

    Article  CAS  PubMed  Google Scholar 

  • Sarasquete ME, González M, San Miguel JF, García-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387

    Article  CAS  PubMed  Google Scholar 

  • Sawcer SJ, Maranian M, Singlehurst S, Yeo T, Compston A, Daly MJ, De Jager PL, Gabriel S, Hafler DA, Ivinson AJ, Lander ES, Rioux JD, Walsh E, Gregory SG, Schmidt S, Pericak-Vance MA, Barcellos L, Hauser SL, Oksenberg JR, Kenealy SJ, Haines JL (2004) Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. Hum Mol Genet 13:1943–1949

    Article  PubMed  Google Scholar 

  • Shapses SA, Kendler DL, Robson R, Hansen KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM, Santora AC 2nd (2011) Effect of alendronate and vitamin D(3) on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. J Bone Miner Res 26:1836–1844

    Article  CAS  PubMed  Google Scholar 

  • Simsek M, Cetin Z, Bilgen T, Taskin O, Luleci G, Keser I (2008) Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. J Obstet Gynaecol Res 34:73–77

    CAS  PubMed  Google Scholar 

  • Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–S13

    Article  PubMed  Google Scholar 

  • Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175–182

    Article  CAS  PubMed  Google Scholar 

  • Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K (2003) Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 1(3):E69

    PubMed Central  PubMed  Google Scholar 

  • Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradóttir S, Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K (2009) New sequence variants associated with bone mineral density. Nat Genet 4:15–17

    Article  CAS  Google Scholar 

  • Tesch G, Amur S, Schousboe JT, Siegel JN, Lesko LJ, Bai JP (2010) Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J 12:243–253

    Article  PubMed Central  PubMed  Google Scholar 

  • Tofteng CL, Bach-Mortensen P, Bojesen SE, Tybjaerg-Hansen A, Hyldstrup L, Nordestgaard BG (2007) Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. Pharmacogenet Genomics 17:85–91

    Article  CAS  PubMed  Google Scholar 

  • Trost Z, Trebse R, Prezelj J, Komadina R, Logar DB, Marc J (2010) A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts. Bone 46:72–80

    Article  CAS  PubMed  Google Scholar 

  • Tsukamoto K, Orimo H, Hosoi T, Miyao M, Ota N, Nakajima T, Yoshida H, Watanabe S, Suzuki T, Emi M (2000 Mar) Association of bone mineral density with polymorphism of the human calcium-sensing receptor locus. Calcif Tissue Int 66(3):181–183

    Article  CAS  PubMed  Google Scholar 

  • U.S. Food and Drug Administration, European Commission, European Medicines Agency (2009) General principles processing joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the Confidentiality Arrangement. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003887.pdf

  • Uitterlinden AG, Ralston SH (2010) Genetics of osteoporosis. Endocr Rev 31:629–662

    Article  CAS  PubMed  Google Scholar 

  • Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amedei A, Bassiti A, Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, Fang Y, Karczmarewicz E, Kruk M, van Leeuwen JP, Mavilia C, van Meurs JB, Mangion J, McGuigan FE, Pols HA, Renner W, Rivadeneira F, van Schoor NM, Scollen S, Sherlock RE, Ioannidis JP, APOSS Investigators, EPOS Investigators, EPOLOS Investigators, FAMOS Investigators, LASA Investigators, Rotterdam Study Investigators, GENOMOS Study (2006) The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med 145:255–264

    Article  CAS  PubMed  Google Scholar 

  • UNESCO (1997) Universal declaration on the human rights. 11th Nov 1997. http://unesdoc.unesco.org/images/0011/001102/110220e.pdf#page=47

  • Unnanuntana A, Gladnick BP, Donnelly E, Lane JM (2010) The assessment of fracture risk. J Bone Joint Surg Am 92:743–753

    Article  PubMed Central  PubMed  Google Scholar 

  • van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellström D, Mosekilde L, Nogues X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP, Uitterlinden AG, GENOMOS Study (2008) Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299:1277–1290

    Article  PubMed Central  PubMed  Google Scholar 

  • van Straaten T, Van Schaik R (2010) Genetic techniques for pharmacogenetic analyses. Curr Pharm Des 16:231–237

    Article  PubMed  Google Scholar 

  • Voy BH (2011) Systems genetics: a powerful approach for gene-environment interactions. J Nutr 141:515–519

    Article  CAS  PubMed  Google Scholar 

  • Wang L (2010) Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med 2:3–22

    Article  CAS  PubMed  Google Scholar 

  • Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529–537

    Article  PubMed  Google Scholar 

  • Weinshilboum RM, Wang L (2006) Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 7:223–245

    Article  CAS  PubMed  Google Scholar 

  • Wilson SG, Reed PW, Andrew T, Barber MJ, Lindersson M, Langdown M, Thompson D, Thompson E, Bailey M, Chiano M, Kleyn PW, Spector TD (2004) A genome-screen of a large twin cohort reveals linkage for quantitative ultrasound of the calcaneus to 2q33-37 and 4q12-21. J Bone Miner Res 19:270–277

    Article  CAS  PubMed  Google Scholar 

  • Wilson SR, Peters C, Saftig P, Brömme D (2009) Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284:2584–2592

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Xiong DH, Liu XG, Guo YF, Tan LJ, Wang L, Sha BY, Tang ZH, Pan F, Yang TL, Chen XD, Lei SF, Yerges LM, Zhu XZ, Wheeler VW, Patrick AL, Bunker CH, Guo Y, Yan H, Pei YF, Zhang YP, Levy S, Papasian CJ, Xiao P, Lundberg YW, Recker RR, Liu YZ, Liu YJ, Zmuda JM, Deng HW (2009) Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet 84(3):388–398. doi:10.1016/j.ajhg.2009.01.025

  • Yazdanpanah N, Rivadeneira F, van Meurs JB, Zillikens MC, Arp P, Hofman A, van Duijn CM, Pols HA, Uitterlinden AG (2007) The 1997 G/T and Sp1 polymorphisms in the collagen type I a1 (COLIA1) gene in relation to changes in femoral neck bone mineral density and the risk of fracture in the elderly: the Rotterdam study. Calcif Tissue Int 81:18–25

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Younes A, Kadin ME (2003) Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21(18):3526–3534

    Article  CAS  PubMed  Google Scholar 

  • Zaghloul NA, Katsanis N (2010) Functional modules, mutational load and human genetic disease. Trends Genet 26:168–176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E (2010) Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375:1729–1736

    Article  PubMed  Google Scholar 

  • Zellerino BC, Milligan SA, Gray JR, Williams MS, Brooks R (2009) Identification and prioritization of quality indicators in clinical genetics: an international survey. Am J Med Genet C Semin Med Genet 151C(3):179–190

    Article  PubMed  Google Scholar 

  • Zhu Z, Xue LM, Han T, Jiao L, Qin LP, Li YS, Zheng HC, Zhang QY (2010) Anti-osteoporotic effects and proteomic characterization of the target and mechanism of an Er-Xian Decoction on osteoblastic UMR-106 and osteoclasts induced from RAW264.7. Molecules 15:4695–4710

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Granada, Spain

    Karen Rojo Venegas, Marisa Cañadas Garre & Miguel A. Calleja Hernández

  2. Pharmacogenetics Unit, Pharmacy Service, Hospital Universitario Virgen de las Nieves, Granada, Spain

    Margarita Aguilera

  3. Instituto de Nutrición y Tecnología de los Alimentos “José Mataix Verdú” de la Universidad de Granada (INYTA), Centro de Investigación Biomédica (CIBM), Granada, Spain

    Margarita Aguilera

Authors
  1. Karen Rojo Venegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margarita Aguilera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marisa Cañadas Garre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel A. Calleja Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margarita Aguilera .

Editor information

Editors and Affiliations

  1. Centre for Genomics & Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, West Bengal, India

    Debmalya Barh

  2. Institute of Life Sciences, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad University, Ahmedabad, Gujarat, India

    Dipali Dhawan

  3. Policy Centre for Biomedical Research, Translational Health Science and Technology Institute (Department of Biotechnology Institute, Government of India), Office @ National Institute of Immunology, New Delhi, India

    Nirmal Kumar Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer India

About this chapter

Cite this chapter

Venegas, K.R., Aguilera, M., Garre, M.C., Hernández, M.A.C. (2013). Pharmacogenomics of Osteoporosis-Related Bone Fractures. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_29

Download citation

Publish with us

Policies and ethics

Search

Navigation